A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Exelixis
Immatics US, Inc.
Fate Therapeutics
Hoffmann-La Roche
Fate Therapeutics